Study peak expiratory flow (PEF) data profile group
| Admission | Following morning* | Discharge | 4 weeks | |
| Actual value of PEF, l/min | ||||
| Montelukast | 227.5 (±56.9) | 389.6 (±109.7)* | 450.1 (±80.6) | 424.1 (±103.6) |
| Placebo | 240.3 (±99.8) | 332.3 (±124.9)* | 408.5 (±105.8) | 436.7 (± 125.5) |
| Difference 95% CI | −50.9 to 25.5 | 1.15 to 113.6* | −2.5 to 85.6 | −77.6 to 52.3 |
| p Value | 0.508 | 0.046* | 0.064 | 0.698 |
| PEF expressed as a percentage of patients best/predicted | ||||
| Montelukast | 47.7 (±11.6) | 81.4 (±19.5) | 94.1 (±14.5) | 89.2 (±19.1) |
| Placebo | 49.6 (±15.3) | 69.8 (±20.7) | 86.1 (±21.2) | 91.5 (±25.4) |
| Difference 95% CI | −8.3 to 4.4 | 2.0 to 21.2 | −0.6 to 16.5 | −15.1 to 10.4 |
| p Value | 0.543 | 0.019 | 0.067 | 0.715 |
Values are given as the mean (±SD).
↵* Primary end point.